- Home
- EOLS vs UPXI Comparison
EOLS vs UPXI Comparison
Compare EOLS & UPXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOLS
- UPXI
- Stock Information
- Founded
- EOLS 2012
- UPXI 2018
- Country
- EOLS United States
- UPXI United States
- Employees
- EOLS N/A
- UPXI N/A
- Industry
- EOLS Biotechnology: Pharmaceutical Preparations
- UPXI Medicinal Chemicals and Botanical Products
- Sector
- EOLS Health Care
- UPXI Health Care
- Exchange
- EOLS Nasdaq
- UPXI Nasdaq
- Market Cap
- EOLS 412.0M
- UPXI 339.4M
- IPO Year
- EOLS 2018
- UPXI 2021
- Fundamental
- Price
- EOLS $6.73
- UPXI $7.35
- Analyst Decision
- EOLS Strong Buy
- UPXI
- Analyst Count
- EOLS 5
- UPXI 0
- Target Price
- EOLS $21.25
- UPXI N/A
- AVG Volume (30 Days)
- EOLS 2.3M
- UPXI 11.3M
- Earning Date
- EOLS 08-05-2025
- UPXI 05-16-2025
- Dividend Yield
- EOLS N/A
- UPXI N/A
- EPS Growth
- EOLS N/A
- UPXI N/A
- EPS
- EOLS N/A
- UPXI N/A
- Revenue
- EOLS $277,941,000.00
- UPXI $16,562,327.00
- Revenue This Year
- EOLS $33.42
- UPXI $299.03
- Revenue Next Year
- EOLS $33.18
- UPXI N/A
- P/E Ratio
- EOLS N/A
- UPXI N/A
- Revenue Growth
- EOLS 17.15
- UPXI 1378.83
- 52 Week Low
- EOLS $5.71
- UPXI $1.90
- 52 Week High
- EOLS $17.82
- UPXI $22.57
- Technical
- Relative Strength Index (RSI)
- EOLS 33.84
- UPXI 57.66
- Support Level
- EOLS $6.21
- UPXI $6.88
- Resistance Level
- EOLS $6.74
- UPXI $8.41
- Average True Range (ATR)
- EOLS 0.45
- UPXI 0.77
- MACD
- EOLS -0.16
- UPXI 0.32
- Stochastic Oscillator
- EOLS 27.49
- UPXI 74.15
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via a Solana treasury strategy.